NCT06706570Recruiting
PIK3CA Mutational Status Assessment
PIK3CA Mutational Status Assessment: Towards a "Tailored" Diagnostic Approach
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 22 Nov 2024
- Start date
- 6 Nov 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- European Institute of Oncology
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06706570
What you commit to
- Study type: Observational
- Planned participants: 100
- From 6 Nov 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients already treated with different treatments like chemotherapy, hormone therapy etc
Who the study is looking for
- Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory.
- Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing.
- Participants should be at advanced or metastatic setting prior to treatment.
- Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
- Patients must be accessible for follow-up.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| European Institute of Oncology Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.